Product Image

Contributor Information

  • Name Ayham Alnabulsi
  • Institute Vertebrate Antibodies Limited

Tool Details

  • Tool name: Anti-Cytochrome P450 4F11 [F21 P6 F5]
  • Clone: F21 P6 F5
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; IHC ; WB
  • Strain: Balb/c
  • Description: Cytochrome P450 4F11 (CYP4F11) encodes a member of the cytochrome P450 superfamily of enzymes that are a group of heme-thiolate monooxygenases. Cytochromes P450 catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. CYP4F11 has catalytic properties towards endogenous eicosanoids as well as some clinically relevant drugs, including benzphetamine, ethylmorphine, chlorpromazine, imipramine and erythromycin. CYP4F11 is expressed in the liver, kidney, heart, brain, and skeletal muscle and is overexpressed in ovarian and colon cancers.
  • Immunogen: Ovalbumin-conjugated synthetic peptide RVEPLGANSQ (C-terminal sequence)
  • Isotype: IgG1 kappa
  • Research area: Cancer; Tissue-specific biology; Cell signaling and signal transduction; Metabolism

  • For Research Use Only

Target Details

  • Target: CYP4F11- Cytochrome P450 4F11 (EC 1.14.14.1) (CYPIVF11)
  • Target background: Cytochrome P450 4F11 (CYP4F11) encodes a member of the cytochrome P450 superfamily of enzymes that are a group of heme-thiolate monooxygenases. Cytochromes P450 catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. CYP4F11 has catalytic properties towards endogenous eicosanoids as well as some clinically relevant drugs, including benzphetamine, ethylmorphine, chlorpromazine, imipramine and erythromycin. CYP4F11 is expressed in the liver, kidney, heart, brain, and skeletal muscle and is overexpressed in ovarian and colon cancers.

Application Details

  • Application: ELISA ; IHC ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15°C to -25°C
  • Shipping conditions: Shipping at 4°C

Documentation

Related Tools

Product Image

Anti-GST [5C12] (ChIP Grade)

#153497
Product Image

Anti-CD22 [RFB-4]

#151335
Product Image

Anti-BORIS [20B11] mAb

#152812

References

  • •  Alnabulsi et al. 2017. Br J Cancer. :. PMID: 28557975.
  • •  The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance.
  • •  Alnabulsi et al. 2016. Characterisation of Arachidonic Acid Metabolising Enzymes in Colorectal Cancer. J Pathol. 240 Suppl 1:S1-S48. PMID: 27747872
  • •  Nottingham Pathology 2016. 9th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 28 June - 1 July 2016.
  • •  Downie et al. 2005. Clin Cancer Res. 11(20):7369-75. PMID: 16243809.
  • •  Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers.
  • •  Kumarakulasingham et al. 2005. Clin Cancer Res. 11(10):3758-65. PMID: 15897573.
  • •  Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis.